A new type of vaccine that can be stored at warmer temperatures, removing the need for refrigeration, has been developed for mosquito-borne virus Chikungunya in a major advance in vaccine technology.
The findings, published in Science Advances today [Wednesday 25 September], reveal exceptionally promising results for the Chikungunya vaccine candidate, which has been engineered using a synthetic protein scaffold that could revolutionise the way vaccines are designed, produced and stored.
Infectious diseases continue to plague populations worldwide. Among the means at our disposal to counter this threat, vaccination has proven to be exceptionally powerful. Smallpox has been eradicated, measles, polio and tetanus constrained from the world by vaccination. However, severe challenges to human health persist, evidenced by epidemics caused by Ebola, Zika and others. This is particularly severe in developing countries which often lack adequate infrastructure and resources to prevent or manage outbreaks, bringing about disruption and damage in affected communities and massive economic shortfall.
A recent example is Chikungunya, a virus transmitted by the bite of an infected mosquito. The disease causes crippling headache, vomiting, swelling of limbs and can lead to death. Even if a fever ends abruptly, chronic symptoms such as intense joint pain, insomnia and extreme prostration remain. Formerly confined to sub-Saharan Africa, Chikungunya has recently spread worldwide as its mosquito host leaves its natural habitat due to deforestation and climate change, with recent outbreaks in USA and Europe causing alarm.
Researchers from the University of Bristol and the French National Centre for Scientific Research (CNRS) in Grenoble, France, teamed up with computer technology giant Oracle to find a way to make vaccines that are thermostable (able to withstand warm temperatures), can be designed quickly and are easily produced.
“We were working with a protein that forms a multimeric particle resembling a virus but is completely safe, because it has no genetic material inside, said Pascal Fender, expert virologist at CNRS. “Completely by chance, we discovered that this particle was incredibly stable even after months, without refrigeration.”
“This particle has a very flexible, exposed surface that can be easily engineered, added Imre Berger, Director of the Max Planck-Bristol Centre for Minimal Biology in Bristol. “We figured that we could insert small, harmless bits of Chikungunya to generate a virus-like mimic we could potentially use as a vaccine.”
To validate their design, the scientists employed cryo-electron microscopy, a powerful new technique recently installed in Bristol’s state-of-the-art microscopy facility headed by Christiane Schaffitzel, co-author of the study. Cryo-EM yields very large data sets from which the structure of a sample can be determined at near atomic resolution, requiring massive parallel computing.
Enabled by Oracle’s high-performance cloud infrastructure, the team developed a novel computational approach to create an accurate digital model of the synthetic vaccine. University of Bristol IT specialists Christopher Woods and Matt Williams, together with colleagues at Oracle, implemented software packages seamlessly on the cloud in this pioneering effort. Christopher explained: “We were able to process the large data sets obtained by the microscope on the cloud in a fraction of the time and at much lower cost than previously thought possible.”
“Researchers have had a long tradition of building and installing their own super computers on-premises, but cloud computing is allowing them to run large data sets in record time, with fast connectivity and low latency. This is helping them crunch data and make scientific breakthroughs much faster. Going forward, technologies like machine learning and cloud computing will play a significant part in the scientific world, and we are delighted we could help the researchers with this important discovery,” added Phil Bates, leading cloud architect at Oracle.
The particles the scientists designed yielded exceptionally promising results in animal studies, soundly setting the stage for a future vaccine to combat Chikungunya disease.
“We were thoroughly delighted,” continued Imre Berger. “Viruses are waiting to strike, and we need to have the tools ready to tackle this global threat. Our vaccine candidate is easy to manufacture, extremely stable and elicits a powerful immune response. It can be stored and transported without refrigeration to countries and patients where it is most needed. Intriguingly, we can now rapidly engineer similar vaccines to combat many other infectious diseases just as well.”
“It really ticks a lot of boxes,” concluded Fred Garzoni, founder of Imophoron Ltd, a Bristol biotech start-up developing new vaccines derived from the present work. “Many challenges in the industry require innovative solutions, to bring powerful new vaccines to patients. Matching cutting-edge synthetic biology with cloud computing turned out to be a winner.”
The Latest on: Synthetic vaccines
via Google News
The Latest on: Synthetic vaccines
- Synthetic Biology Market to Witness Impressive Growth During 2021-2026on May 17, 2021 at 6:05 am
Synthetic Biology Market is likely to witness an impressive CAGR of 23.9% during the forecast period. Increasing use of synthetic biology for various applications such as biofuel development, protein ...
- Pfizer and Moderna vaccines produce robust immune responses in pregnant and nursing womenon May 13, 2021 at 8:23 am
The results of the Beth Israel study are similar to those in another study published in March in the American Journal of Obstetrics and Gynecology by researchers from Massachusetts General Hospital ...
- The Pfizer-BioNTech vaccine is a top target of conspiracy theorieson May 13, 2021 at 7:13 am
Bots and anti-vaccination influencers are amplifying political and medical conspiracy theories around COVID-19 vaccines.
- Kids and the Covid-19 vaccine: A pediatrician answers safety questionson May 13, 2021 at 5:43 am
A leading pediatrician and vaccine expert answers parents' concerns about the safety of the Covid-19 vaccine for teens between the ages of 12 and 15.
- A 'Universal Vaccine' May Soon Protect Against All Coronaviruses, Including the Common Coldon May 12, 2021 at 2:00 am
Even as scientists race to develop booster shots and tweak existing vaccines to work against new variants to SARS2, they're looking ahead to future pandemics caused by entirely new pathogens from the ...
- Personalized vaccine can provide effective immunization against canceron May 11, 2021 at 10:17 am
Marie-Claude Bourgeois-Daigneault and her team at the CRCHUM are using mice to show how a combination of peptides and oncolytic viruses, used as an adjuvant, can provide effective immunization against ...
- Synthetic Biology Market worth $ 11.00 Billion, Globally, by 2028 at 6.60% % CAGR: Verified Market Research™on May 11, 2021 at 8:15 am
Verified Market Research recently published a report, "Synthetic Biology Market" By Product (Core Products and Enabling Products), By Technology (Gene Synthesis, Genome Engineering, Cloning, ...
- A personalized anti-cancer vaccine that works in miceon May 11, 2021 at 6:57 am
In her laboratory at the University of Montreal Hospital Research Centre (CRCHUM), Marie-Claude Bourgeois-Daigneault and a team of scientists usually modify viruses to make them specific to the cells ...
- Coronavirus vaccine development story is a valiant race to save liveson May 9, 2021 at 3:58 pm
All vaccines are very efficacious in preventing severe disease and hospitalization. U.S. infection and hospitalization has been dramatically falling, ...
- COVID-19 vaccine does not spread by inhalation or skin contacton May 8, 2021 at 11:00 am
CLAIM: Pfizer admits in its COVID-19 clinical trial protocol document that vaccinated people can “shed” the vaccine, emitting materials that can spread to unvaccinated people by inhalation or skin ...
via Bing News